In this study, we demonstrated for the first time that osimertinib may be involved in the suppression of cell proliferation via the EphB4 and p53-p21-Cyclin D1 pathway independent of the EGFR pathway in lung carcinoma (Figure 6). Here, EPHB4 is linked to lung carcinoma.